Investment prompts trial tech expansion at Exco InTouch

- Last updated on GMT

Related tags: Exco intouch, Contract research organization, Clinical trial

Exco InTouch is to accelerate expansion in clinical technology after a venture capital group invested in the company.

Scottish Equity Partners (SEP) has taken a minority stake in Exco InTouch having led a £3m ($4.7m) investment. Exco InTouch will use the funds to accelerate expansion in clinical trial technologies, particularly in mobile patient communication.

Jan Rutherford, a partner at SEP, said: “[Exco InTouch] is conducting pioneering work with world leaders in drug development which is helping to make healthcare more efficient, effective, accessible and patient-centric​.”

Rutherford has joined Exco InTouch as a non-executive director and worked at Quintiles, Novartis and Merck & Co before entering the venture capital sector. Other investments Rutherford works with include contract research organisation (CRO) Cmed and health informatics business Aridhia.

Neil Rotherham, executive chairman of Exco InTouch said: “We were attracted to SEP’s extensive industry experience and heavy investment in the market sector we work in. SEP will be able to complement and challenge us, as well as helping our continuing growth​.”

Expansion efforts

Exco InTouch has expanded to 40 employees in 2011 by moving to a larger US headquarters in Cary, North Carolina and opening a second UK office in Nottingham. The Nottingham office can house 30 staff.

The company raised its profile on both sides of the Atlantic by working with Pfizer on its REMOTE clinical trial​. Exco InTouch is providing its eDiary technology so patients can track their symptoms on mobile phones.

Beyond clinical trials Exco InTouch plans to use its mobile technology for patient education and treatment compliance.

Related news

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us


View more